We are live on ! Find out more
SLXP

SALIX PHARMACEUTICALS LTD DEL
SLXP

Delisted

SLXP was delisted on the 31st of March, 2015.

304 hedge funds and large institutions have $6.82B invested in SALIX PHARMACEUTICALS LTD DEL in 2014 Q1 according to their latest regulatory filings, with 78 funds opening new positions, 110 increasing their positions, 98 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

359% more first-time investments, than exits

New positions opened: 78 | Existing positions closed: 17

173% more call options, than puts

Call options by funds: $81.1M | Put options by funds: $29.7M

67% more funds holding in top 10

Funds holding in top 10: 610 (+4)

24% more funds holding

Funds holding: 246304 (+58)

12% more repeat investments, than reductions

Existing positions increased: 110 | Existing positions reduced: 98

8% more capital invested

Capital invested by funds: $6.3B → $6.82B (+$520M)

Holders
304
Holders Change
+58
Holders Change %
+23.58%
% of All Funds
8.78%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.29%
New
78
Increased
110
Reduced
98
Closed
17
Calls
$81.1M
Puts
$29.7M
Net Calls
+$51.5M
Net Calls Change
+$4.64M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$814M +$33.1M +323,352 +4%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$733M -$6.94M -67,790 -0.9%
Vanguard Group
3
Vanguard Group
Pennsylvania
$427M +$55.3M +539,834 +15%
BFA
4
BlackRock Fund Advisors
California
$269M -$1.4M -13,720 -0.5%
Bank of New York Mellon
5
Bank of New York Mellon
New York
$238M -$95.2M -929,725 -29%
State Street
6
State Street
Massachusetts
$197M -$1.75M -17,092 -0.9%
BIT
7
BlackRock Institutional Trust
California
$195M +$18.8M +183,170 +11%
VAM
8
Visium Asset Management
New York
$183M +$74.2M +724,497 +70%
Ameriprise
9
Ameriprise
Minnesota
$176M -$37.1M -362,789 -18%
TCM
10
TimesSquare Capital Management
New York
$173M -$23M -224,950 -12%
Viking Global Investors
11
Viking Global Investors
Connecticut
$161M +$159M +1,551,766 New
Federated Hermes
12
Federated Hermes
Pennsylvania
$148M -$38.7M -377,805 -21%
TCIM
13
TIAA CREF Investment Management
New York
$120M -$145M -1,414,571 -55%
Wells Fargo
14
Wells Fargo
California
$116M +$1.65M +16,116 +1%
Bank of America
15
Bank of America
North Carolina
$112M -$4.81M -46,943 -4%
Invesco
16
Invesco
Georgia
$107M +$3M +29,349 +3%
William Blair & Company
17
William Blair & Company
Illinois
$105M +$19M +185,281 +22%
EAM
18
Eagle Asset Management
Florida
$78M -$39.9M -389,886 -34%
Fidelity International
19
Fidelity International
Bermuda
$75.4M +$7.27M +70,997 +11%
HM
20
HealthCor Management
New York
$67.3M +$25.6M +250,000 +63%
Franklin Resources
21
Franklin Resources
California
$65.4M -$39.8M -388,740 -38%
American Century Companies
22
American Century Companies
Missouri
$61.9M +$59.2M +578,568 +3,016%
Northern Trust
23
Northern Trust
Illinois
$60.1M +$9.56M +93,349 +19%
First Trust Advisors
24
First Trust Advisors
Illinois
$53.6M +$22.5M +219,628 +74%
JP Morgan Chase
25
JP Morgan Chase
New York
$52.4M +$36M +351,196 +228%

SLXP Hedge Fund Activity: Q1 2014 in Review

304 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in SALIX PHARMACEUTICALS LTD DEL (SLXP) for Q1 2014, worth a combined $6.82B — up 8.3% from $6.3B a quarter earlier.

Buyers outnumbered sellers: 78 funds opened new SLXP positions and 17 closed out — a net gain of 61 holders — while 110 added to existing stakes and 98 trimmed.

The largest buyer was Viking Global Investors, opening a new position worth an estimated $159M. The largest seller was TIAA CREF Investment Management, cutting an estimated $145M.

  • 304 institutional investors held SALIX PHARMACEUTICALS LTD DEL (SLXP) as of Q1 2014, up from 246 in Q4 2013.
  • Funds reported $6.82B of SALIX PHARMACEUTICALS LTD DEL stock for Q1 2014, up 8.3% quarter-over-quarter.
  • 78 funds opened new SALIX PHARMACEUTICALS LTD DEL positions in Q1 2014 and 17 closed out, a net change of +61 holders.
  • The largest SALIX PHARMACEUTICALS LTD DEL buyer in Q1 2014 was Viking Global Investors, an estimated $159M added.
  • The largest SALIX PHARMACEUTICALS LTD DEL seller in Q1 2014 was TIAA CREF Investment Management, an estimated $145M sold.

Based on aggregated 13F filings for Q1 2014.